- Home
- LOAN vs CGTX Comparison
LOAN vs CGTX Comparison
Compare LOAN & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOAN
- CGTX
- Stock Information
- Founded
- LOAN 1989
- CGTX 2007
- Country
- LOAN United States
- CGTX United States
- Employees
- LOAN N/A
- CGTX N/A
- Industry
- LOAN Real Estate Investment Trusts
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- LOAN Real Estate
- CGTX Health Care
- Exchange
- LOAN Nasdaq
- CGTX Nasdaq
- Market Cap
- LOAN 61.5M
- CGTX 53.4M
- IPO Year
- LOAN 1999
- CGTX 2021
- Fundamental
- Price
- LOAN $5.37
- CGTX $1.47
- Analyst Decision
- LOAN
- CGTX Strong Buy
- Analyst Count
- LOAN 0
- CGTX 3
- Target Price
- LOAN N/A
- CGTX $2.83
- AVG Volume (30 Days)
- LOAN 21.2K
- CGTX 8.1M
- Earning Date
- LOAN 10-22-2025
- CGTX 11-12-2025
- Dividend Yield
- LOAN 8.60%
- CGTX N/A
- EPS Growth
- LOAN N/A
- CGTX N/A
- EPS
- LOAN 0.48
- CGTX N/A
- Revenue
- LOAN $7,300,469.00
- CGTX N/A
- Revenue This Year
- LOAN N/A
- CGTX N/A
- Revenue Next Year
- LOAN $4.47
- CGTX N/A
- P/E Ratio
- LOAN $11.15
- CGTX N/A
- Revenue Growth
- LOAN N/A
- CGTX N/A
- 52 Week Low
- LOAN $4.74
- CGTX $0.22
- 52 Week High
- LOAN $6.05
- CGTX $3.83
- Technical
- Relative Strength Index (RSI)
- LOAN 49.82
- CGTX 39.92
- Support Level
- LOAN $5.28
- CGTX $1.43
- Resistance Level
- LOAN $5.44
- CGTX $2.60
- Average True Range (ATR)
- LOAN 0.11
- CGTX 0.31
- MACD
- LOAN 0.00
- CGTX -0.19
- Stochastic Oscillator
- LOAN 75.00
- CGTX 2.94
About LOAN Manhattan Bridge Capital Inc
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.